Lung cancer in women: role of estrogens

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin.55(2), 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin.59(4), 225–249 (2009).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J. Clin.56(2), 106–130 (2006).
   PubMed Web of Science ®Google Scholar
• Bray F, Tyczynski JE, Parkin DM. Going up or coming down? The changing phases of the lung cancer epidemic from 1967 to 1999 in the 15 European Union countries. Eur. J. Cancer40(1), 96–125 (2004).
   PubMed Web of Science ®Google Scholar
• Howe HL, Wingo PA, Thun MJ et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J. Natl Cancer Inst.93(11), 824–842 (2001).
   PubMed Web of Science ®Google Scholar
• Taioli E, Wynder EL. Re: Endocrine factors and adenocarcinoma of the lung in women. J. Natl Cancer Inst.86(11), 869–870 (1994).
   PubMed Web of Science ®Google Scholar
• Adami HO, Persson I, Hoover R, Schairer C, Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int. J. Cancer44(5), 833–839 (1989).
   PubMed Web of Science ®Google Scholar
• Schabath MB, Wu X, Vassilopoulou-Sellin R, Vaporciyan AA, Spitz MR. Hormone replacement therapy and lung cancer risk: a case–control analysis. Clin. Cancer Res.10(1 Pt 1), 113–123 (2004).
   PubMed Web of Science ®Google Scholar
• Ramnath N, Menezes RJ, Loewen G et al. Hormone replacement therapy as a risk factor for non-small cell lung cancer: results of a case–control study. Oncology73(5–6), 305–310 (2007).
   PubMed Web of Science ®Google Scholar
• Schwartz AG, Wenzlaff AS, Prysak GM et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J. Clin. Oncol.25(36), 5785–5792 (2007).
   PubMed Web of Science ®Google Scholar
• Chen KY, Hsiao CF, Chang GC et al. Hormone replacement therapy and lung cancer risk in Chinese. Cancer110(8), 1768–1775 (2007).
   PubMed Web of Science ®Google Scholar
• Koushik A, Parent ME, Siemiatycki J. Characteristics of menstruation and pregnancy and the risk of lung cancer in women. Int. J. Cancer125(10), 2428–2433 (2009).
   PubMedGoogle Scholar
• Moore KA, Mery CM, Jaklitsch MT et al. Menopausal effects on presentation, treatment, and survival of women with non-small cell lung cancer Ann. Thorac. Surg.76(6), 1789–1795 (2003).
   PubMed Web of Science ®Google Scholar
• Ganti AK, Sahmoun AE, Panwalkar AW, Tendulkar KK, Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J. Clin. Oncol.24(1), 59–63 (2006).
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Schwartz AG, Wakelee H et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women’s Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet374(9697), 1243–1251 (2009).
   PubMed Web of Science ®Google Scholar
• Huang B, Carloss H, Wyatt SW, Riley E. Hormone replacement therapy and survival in lung cancer in postmenopausal women in a rural population. Cancer115(18), 4167–4175 (2009).
   PubMedGoogle Scholar
• Ayeni O, Robinson A. Hormone replacement therapy and outcomes for women with non-small-cell lung cancer: can an association be confirmed? Curr. Oncol.16(3), 21–25 (2009).
   PubMedGoogle Scholar
• Weinberg OK, Marquez-Garban DC, Fishbein MC et al. Aromatase inhibitors in human lung cancer therapy. Cancer Res.65(24), 11287–11291 (2005).
   PubMed Web of Science ®Google Scholar
• Stabile LP, Davis AL, Gubish CT et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor α and β and show biological responses to estrogen. Cancer Res.62(7), 2141–2150 (2002).
   PubMed Web of Science ®Google Scholar
• Pietras RJ, Marquez DC, Chen HW, Tsai E, Weinberg O, Fishbein M. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids70(5–7), 372–381 (2005).
   PubMed Web of Science ®Google Scholar
• Marquez-Garban DC, Chen HW, Fishbein MC, Goodglick L, Pietras RJ. Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids72(2), 135–143 (2007).
   PubMedGoogle Scholar
• Deroo BJ, Korach KS. Estrogen receptors and human disease. J. Clin. Invest.116(3), 561–570 (2006).
   PubMed Web of Science ®Google Scholar
• Kawai H, Ishii A, Washiya K et al. Estrogen receptor α and β are prognostic factors in non-small cell lung cancer. Clin. Cancer Res.11(14), 5084–5089 (2005).
   PubMedGoogle Scholar
• Hershberger PA, Vasquez AC, Kanterewicz B, Land S, Siegfried JM, Nichols M. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res.65(4), 1598–1605 (2005).
   PubMed Web of Science ®Google Scholar
• Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N. Engl. J. Med.346(5), 340–352 (2002).
   PubMed Web of Science ®Google Scholar
• Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α: a new model for anti-estrogen resistance. J. Biol. Chem.276(13), 9817–9824 (2001).
   PubMed Web of Science ®Google Scholar
• Chen D, Riedl T, Washbrook E et al. Activation of estrogen receptor α by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol. Cell.6(1), 127–137 (2000).
   PubMed Web of Science ®Google Scholar
• Fasco MJ, Hurteau GJ, Spivack SD. Gender-dependent expression of α and β estrogen receptors in human nontumor and tumor lung tissue. Mol. Cell. Endocrinol.188(1–2), 125–140 (2002).
   PubMed Web of Science ®Google Scholar
• Pfeffer U, Fecarotta E, Castagnetta L, Vidali G. Estrogen receptor variant messenger RNA lacking exon 4 in estrogen-responsive human breast cancer cell lines. Cancer Res.53(4), 741–743 (1993).
   PubMedGoogle Scholar
• Schwartz AG, Prysak GM, Murphy V et al. Nuclear estrogen receptor β in lung cancer: expression and survival differences by sex. Clin. Cancer Res.11(20), 7280–7287 (2005).
   PubMed Web of Science ®Google Scholar
• Issa JP, Baylin SB, Belinsky SA. Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure. Cancer Res.56(16), 3655–3658 (1996).
   PubMed Web of Science ®Google Scholar
• Hammoud Z, Tan B, Badve S, Bigsby RM. Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma. Endocr. Relat. Cancer15(2), 475–483 (2008).
   PubMedGoogle Scholar
• Burger HG. Androgen production in women. Fertil. Steril.77(Suppl. 4), S3–S5 (2002).
   PubMed Web of Science ®Google Scholar
• Su JM, Hsu HK, Chang H et al. Expression of estrogen and progesterone receptors in non-small-cell lung cancer: immunohistochemical study. Anticancer Res.16(6B), 3803–3806 (1996).
   PubMedGoogle Scholar
• Kaiser U, Hofmann J, Schilli M et al. Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int. J. Cancer67(3), 357–364 (1996).
   PubMedGoogle Scholar
• Ishibashi H, Suzuki T, Suzuki S et al. Progesterone receptor in non-small cell lung cancer – a potent prognostic factor and possible target for endocrine therapy. Cancer Res.65(14), 6450–6458 (2005).
   PubMedGoogle Scholar
• Raso MG, Behrens C, Herynk MH et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin. Cancer Res.15(17), 5359–5368 (2009).
   PubMed Web of Science ®Google Scholar
• Mah V, Seligson DB, Li A et al. Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res.67(21), 10484–10490 (2007)
   PubMedGoogle Scholar
• Marquez-Garban DC, Chen HW, Goodglick L, Fishbein MC, Pietras RJ. Targeting aromatase and estrogen signaling in human non-small cell lung cancer. Ann. NY Acad. Sci.1155, 194–205 (2009).
   PubMedGoogle Scholar
• Chen Y, Perng RP, Yang KY et al. Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy. Lung Cancer29(2), 139–146 (2000).
   PubMedGoogle Scholar
• Chen YM, Perng RP, Yang KY et al. A Phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin combination chemotherapy for inoperable non-small-cell lung cancer. Am. J. Clin. Oncol.23(1), 13–17 (2000).
   PubMedGoogle Scholar
• Traynor AM, Schiller JH, Stabile LP et al. Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer64(1), 51–59 (2009).
   PubMedGoogle Scholar
• Collins IM, Nicholson SA, O’Byrne KJ. A lung cancer responding to hormonal therapy. J. Thorac. Oncol.5(5), 749–750 (2010).
   PubMedGoogle Scholar
• McClay EF, Bogart J, Herndon JE 2nd et al. A Phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235). Am. J. Clin. Oncol.28(1), 81–90 (2005).
   PubMedGoogle Scholar
• Blackman JA, Coogan PF, Rosenberg L et al. Estrogen replacement therapy and risk of lung cancer. Pharmacoepidemiol. Drug Saf.11(7), 561–567 (2002).
   PubMed Web of Science ®Google Scholar
• Kreuzer M, Gerken M, Heinrich J, Kreienbrock L, Wichmann HE. Hormonal factors and risk of lung cancer among women? Int. J. Epidemiol.32(2), 263–271 (2003).
   PubMed Web of Science ®Google Scholar
• Smith JR, Barrett-Connor E, Kritz-Silverstein D, Wingard DL, Al-Delaimy WK. Hormone use and lung cancer incidence: the Rancho Bernardo cohort study. Menopause16(5), 1044–1048 (2009).
   PubMed Web of Science ®Google Scholar
• Slatore CG, Chien JW, Au DH, Satia JA, White E. Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J. Clin. Oncol.28(9), 1540–1546 (2010).
   PubMed Web of Science ®Google Scholar
• Di Nunno L, Larsson LG, Rinehart JJ, Beissner RS. Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. Arch. Pathol. Lab. Med.124(10), 1467–1470 (2000).
   PubMedGoogle Scholar
• Radzikowska E, Langfort R, Giedronowicz D. Estrogen and progesterone receptors in non small cell lung cancer patients. Ann. Thorac. Cardiovasc. Surg.8(2), 69–73 (2002).
   PubMedGoogle Scholar